Table 7.
Patient baseline demographics in a study comparing azithromycin 2.0 g microspheres with levofloxacin 500 mg in acute exacerbations of chronic bronchitis (Zervos et al 2005)
| Characteristic | Azithromycin microspheres (n = 268) | Levofloxacin 500 mg (n = 2742) |
|---|---|---|
| Mean age (years) | 62.3 | 61.7 |
| Systemic steroids | 27 (10.1%) | 27 (9.9%) |
| FEV1 % predicted | ||
| >80 | 44 (16.4%) | 35 (12.8%) |
| <80 and >60 | 50 (18.7%) | 57 (20.8%) |
| <60 and >30 | 111 (41.4%) | 110 (40.1%) |
| <30 | 31 (11.6%) | 38 (13.9%) |
| Missing | 32 (11.9%) | 34 (12.4%) |
| Smoking history | ||
| Smoker | 156 (58.2%) | 163 (59.5%) |
| Ex-smoker | 109 (40.7%) | 111 (40.5%) |
| Never-smoker | 3 (1.1%) | 0 (0%) |
| Anthonisen criteria | ||
| Presence of all three criteria | 263 (98.1%) | 269 (98.2%) |
| Presence of two criteria | 5 (1.9%) | 4 (1.5%) |
| Presence of one criterion | 0 (0%) | 1 (0.4%) |
| No. AECB in the previous year | ||
| 1–4 | 213 (79.5%) | 218 (79.6%) |
| >4 | 21 (7.8%) | 21 (7.7%) |
| None | 34 (12.7%) | 34 (12.4%) |
Abbreviations: AECB, acute exacerbations of chronic bronchitis; FEV1, forced expiratory volume in 1 second; Anthonisen criteria: increased cough, increased in sputum production, change in sputum color.